drugset / Trial / NCT00070642

CPG 7909 Injection in Melanoma

NCT00070642

Phase 2 Completed 184 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.

Timeline

Start
2003-12
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 850 mg/m2
Subject agatolimod Oligonucleotide (other) 10 mg Subcutaneous
Subject agatolimod Oligonucleotide (other) 40 mg Subcutaneous

Indications